Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Rupert Bartsch, Florian Fitzal et al.|OncoImmunology|2023Cited by 30
187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)Rupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|ESMO Open|2024Cited by 15
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Michael Gnant, Zsuzsanna Bagó-Horváth et al.|Breast Care|2025Cited by 3
Abstract P3-06-10: Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)Maximilian Marhold, Rupert Bartsch, Kerstin Wimmer et al.|Cancer Research|2023Cited by 2